Breakthrough Dual Therapy Protocol BICOV-1 Offers New Hope for Advanced Ovarian Cancer Treatment

What is the New BICOV-1 Treatment Breakthrough?

Spanish researchers have launched the BICOV-1 trial to evaluate a novel combined intraperitoneal chemotherapy approach for advanced ovarian cancer. The phase I study will assess the safety and efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) followed by normothermic intraperitoneal chemotherapy long-term (NIPEC-LT) in patients undergoing interval cytoreductive surgery. This dual approach represents the first clinical protocol combining these two established intraperitoneal treatment modalities in ovarian cancer management.

Ovarian cancer remains the leading cause of death among gynecologic malignancies, with more than two-thirds of patients presenting with peritoneal dissemination at diagnosis. Despite advances in surgical techniques and systemic therapies, recurrence rates remain high even after complete cytoreduction, primarily due to residual microscopic disease. The BICOV-1 trial builds upon substantial evidence supporting intraperitoneal chemotherapy approaches, including the landmark OVHIPEC-1 trial which demonstrated significant survival benefits when HIPEC was added to interval cytoreductive surgery. That pivotal study showed median overall survival increased from 33.9 to 45.7 months with HIPEC, while progression-free survival improved from 10.7 to 14.2 months. Similar benefits were observed in trials by Cascales-Campos and colleagues, which reported disease-free survival extensions from 12 to 18 months, and by Lim et al., whose study found median overall survival increased from 48.2 to 61.8 months in the neoadjuvant chemotherapy subgroup receiving HIPEC during interval cytoreduction. Despite these impressive results, a key limitation of HIPEC has been its single-administration nature, which the BICOV-1 protocol aims to address by adding multiple cycles of NIPEC-LT following surgery and HIPEC.

How Does the Combined Protocol Enhance Therapeutic Outcomes?

The BICOV-1 protocol includes a standardized surgical approach requiring complete cytoreduction (CC-0 score) before proceeding to HIPEC treatment. Following cytoreduction, patients receive cisplatin-based HIPEC (100 mg/m² at 42°C for 90 minutes) with sodium thiosulfate to prevent nephrotoxicity. A specialized intraperitoneal catheter is then placed for subsequent NIPEC-LT administration. Between 30-60 days post-surgery, patients begin four cycles of NIPEC-LT administered every 21 days, following a regimen adapted from Armstrong and modified by the Spanish Ovarian Cancer Research Group: intravenous paclitaxel on day 1, intraperitoneal cisplatin on day 2, and intraperitoneal paclitaxel on day 8. The primary endpoint focuses on safety, monitoring adverse events according to NCI-CTCAE criteria and evaluating the percentage of patients completing the full treatment protocol. Secondary endpoints include disease-free and overall survival at 1, 3, and 5 years, alongside quality-of-life assessments using validated instruments. "The rationale for combining these two modalities is compelling," said Dr. Pablo Cascales-Campos, principal investigator from Hospital Clínico Universitario Virgen de la Arrixaca. "Their complications don't overlap temporally, and both have independently demonstrated survival benefits in advanced ovarian cancer."

The scientific rationale for this combined approach extends beyond practical considerations. Researchers hypothesize that HIPEC creates favorable biological changes in the tumor microenvironment that may enhance the efficacy of subsequent NIPEC-LT cycles. HIPEC induces multiple cellular and molecular alterations, including increased apoptosis, inhibition of DNA repair mechanisms, enhanced cell membrane permeability, and activation of antitumor immune responses. These changes potentially create a more vulnerable tumor environment for subsequent chemotherapy cycles. The hyperthermia component of HIPEC increases cellular permeability and optimizes drug uptake, while simultaneously triggering heat shock proteins that promote apoptosis and enhance immune recognition of tumor cells. Additionally, HIPEC has been shown to inhibit homologous recombination DNA repair, potentially sensitizing tumor cells to platinum-based drugs used in the NIPEC-LT phase. These biological effects suggest that the sequential application of these two intraperitoneal treatment modalities may produce synergistic rather than merely additive benefits. The trial has received approval from the Clinical Research and Ethics Committee of Hospital Clínico Universitario Virgen de la Arrixaca and authorization from the Spanish Agency of Medicines and Medical Devices. It is registered in multiple clinical trial databases, including ClinicalTrials.gov (NCT06902467).

Can the Dual Approach Disrupt Current Treatment Paradigms?

The BICOV-1 approach represents a significant advancement compared to current standard treatments for advanced ovarian cancer. While intravenous chemotherapy remains the mainstay of systemic treatment, it often fails to adequately target peritoneal disease due to the peritoneal-plasma barrier. Standalone HIPEC has gained traction following positive trial results, but its single administration limits its impact on microscopic disease that may persist or develop after surgery. Similarly, while NIPEC-LT showed promise in early GOG trials, issues with toxicity and catheter complications have limited its widespread adoption. The combined approach being tested in BICOV-1 could potentially address these limitations by capitalizing on the immediate impact of HIPEC while extending treatment benefits through multiple NIPEC-LT cycles. This positions the protocol as a potentially competitive option against both standard IV chemotherapy and emerging targeted therapies, including PARP inhibitors and anti-angiogenic agents. If successful, this approach could significantly influence treatment guidelines and market dynamics in ovarian cancer management. The trial results will also have implications for pharmaceutical companies developing intraperitoneal delivery systems and chemotherapy formulations optimized for peritoneal administration.

Looking ahead, the investigators plan to use data from this phase I trial to design phase II and III studies comparing the administration or omission of NIPEC-LT following interval cytoreductive surgery with HIPEC. "This initial safety study will provide crucial information about the feasibility of intensifying intraperitoneal treatment in patients who have already undergone extensive surgery and HIPEC," noted Dr. Cascales-Campos. The researchers anticipate that if safety endpoints are met, subsequent efficacy trials could potentially demonstrate further improvements in survival outcomes beyond what has been achieved with either modality alone. The trial may also help refine patient selection criteria and optimize treatment protocols, particularly regarding the timing, dosing, and duration of NIPEC-LT following HIPEC. The broader implications of this research extend to other peritoneal malignancies where similar combined approaches might be beneficial.

Industry Context: The BICOV-1 trial reflects the growing trend toward multimodal, intensified local-regional treatments in oncology, particularly for cancers with peritoneal dissemination. This approach aligns with the industry's shift toward combination therapies that target different aspects of tumor biology and address the limitations of single-modality treatments. For pharmaceutical companies, successful results could drive interest in developing specialized delivery systems and formulations optimized for intraperitoneal administration. For healthcare systems, the potential survival benefits must be weighed against the resources required for implementing complex surgical-chemotherapeutic protocols, highlighting the importance of the cost-effectiveness analyses that will follow this initial safety study.

Summary

The BICOV-1 trial represents a pioneering approach in advanced ovarian cancer treatment, combining HIPEC and NIPEC-LT therapies following interval cytoreductive surgery. This phase I study builds upon previous successful trials that demonstrated significant survival benefits with HIPEC alone. The protocol involves complete cytoreduction followed by cisplatin-based HIPEC and four cycles of NIPEC-LT. The scientific rationale suggests potential synergistic benefits, as HIPEC-induced biological changes may enhance NIPEC-LT effectiveness. The trial aims to address limitations of current treatments while evaluating safety, survival outcomes, and quality of life measures, potentially establishing a new standard in ovarian cancer management.